-+ 0.00%
-+ 0.00%
-+ 0.00%
MetaVia's DA-1726 matches retatrutide weight loss in mouse study
Share
Listen to the news
MetaVia's DA-1726 matches retatrutide weight loss in mouse study
  • MetaVia reported preclinical results showing DA-1726 matched retatrutide’s weight loss with less appetite suppression in obese mice.
  • Results presented Nov. 14, 2026, at ObesityWeek also showed greater glucose lowering and increased levels of a liver hormone involved in metabolism.
  • The findings support plans to begin a Phase 2 trial in MetALD and ALD in the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY97436) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending